Table 1.
Characteristics of control subjects (CSs) and first-episode psychosis (FEP) patients at baseline (before treatment with antipsychotics (FEPb), after 0.6-year treatment (FEP0.6-year), and after 5.1-year treatment (FEP5.1-year) with antipsychotics.
| Characteristics | Participants | Comparison between groups | ||||
|---|---|---|---|---|---|---|
| CSs | FEPb | FEP(0.6-year) | FEP(5.1-year) | FEPb and CSs | FEPb, FEP(0.6-year), and FEP(5.1-year) | |
| Participants | 37 | 52 | 44 | 37 | ||
| Age (years),(mean ± SD) | 24.9 ± 5.3 | 27.0 ± 6.1 | 27.7 ± 6.5 | 32.0 ± 5.9 |
t(87) = 1.74 ns |
– |
| Women (%) | 21 (57%) | 21 (40%) | 18 (41%) | 14 (38%) |
Χ2(1) = 2.33 ns |
– |
| Current cigarette smoker (n,%) | 5 (14%) | 17 (33%) | 14 (32%) | 18 (49%) |
χ2(1) = 4.27 p = 0.04 |
χ2(2) = 1.33 ns |
| Weight (kg), (mean ± SD) | 71.6 ± 15.0 | 70.2 ± 13.5 | 77.6 ± 16.2 | 85.8 ± 17.4c |
t(87) = -0.44 ns |
F(2) = 11.48 p < 3e−05 |
| BMI (kg/m2), (mean ± SD) | 23.0 ± 3.1 | 22.8 ± 3.0 | 25.4 ± 4.0a | 27.8 ± 4.5b,c |
t(87) = -0.23 ns |
F(2) = 19.56 p < 1e-06 |
| Waist circumference (cm), (mean ± SD) | 80 ± 12 | 81 ± 10 | 87 ± 11 | 95 ± 11b,c |
t(89) = 0.53 ns |
F(2) = 17.46 p < 1e-06 |
| BPRS score (mean ± SD) | – | 49.9 ± 15.5 | 23.3 ± 12.7a | 14.1 ± 10.6b,c | – |
F(2) = 87.31 p < 1e−06 |
| AP dose (mean ± SD) | – | – | 358 ± 162 | 418 ± 236 | – |
t(36) = −1.28 ns |
BMI body mass index, BPRS Brief Psychiatric Rating Scale, AP dose chlorpromazine equivalent dose of antipsychotics.
ns not significant (p ≥ 0.05).
aStatistically significant difference (p < 0.05) between patients before (FEPb) and after 0.6-year treatment (FEP(0.6-year)).
bStatistically significant difference (p < 0.05) between 0.6-year (FEP(0.6-year)) and 5.1-year treatment (FEP(5.1-year)).
cStatistically significant difference (p < 0.05) between patients before (FEPb) and after 5.1-year treatment (FEP(5.1-year)).